Philippe Ravassard

Philippe Ravassard

Auto-generated profile, based on publicly available information

Philippe Ravassard

Paris Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Paris, France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PRPhilippe Ravassard
Philippe Ravassard
YHYasmine Hazhouz
Yasmine Hazhouz
SPSéverine Pechberty
Séverine Pechberty
EBEmilie Bricout-Neveu
Emilie Bricout-Neveu
MAMathieu Armanet
Mathieu Armanet
RSRaphaël Scharfmann
Raphaël Scharfmann
Despite intense efforts over the past 30 years, human pancreatic β cell lines have not been available. Here, we describe a robust technology for producing a functional human β cell line using targeted oncogenesis in human fetal tissue. Human fetal pancreatic buds were transduced with a lentiviral vector that expressed SV40LT under the control of the insulin promoter. The transduced buds were then grafted into SCID mice so that they could develop into mature pancreatic tissue. Upon differentiation, the newly formed SV40LT-expressing β cells proliferated and formed insulinomas. The resulting β cells were then transduced with human telomerase reverse transcriptase (hTERT), grafted into other SCID mice, and finally expanded in vitro to generate cell lines. One of these cell lines, EndoC-βH1, expressed many β cell–specific markers without any substantial expression of markers of other pancreatic cell types. The cells secreted insulin when stimulated by glucose or other insulin secretagogues, and cell transplantation reversed chemically induced diabetes in mice. These cells represent a unique tool for large-scale drug discovery and provide a preclinical model for cell replacement therapy in diabetes. This technology could be generalized to generate other human cell lines when the cell type–specific promoter is available.

1 July 2002 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
CGChristelle Gras
Christelle Gras
EHEtienne Herzog
Etienne Herzog
GBGian Carlo Bellenchi
Gian Carlo Bellenchi
VBVeronique Bernard
Veronique Bernard
PRPhilippe Ravassard
Philippe Ravassard
SMSalah El Mestikawy
Salah El Mestikawy
Two proteins previously known as Na+-dependent phosphate transporters have been identified recently as vesicular glutamate transporters (VGLUT1 and VGLUT2). Together, VGLUT1 and VGLUT2 are operating at most central glutamatergic synapses. In this study, we characterized a third vesicular glutamate transporter (VGLUT3), highly homologous to VGLUT1 and VGLUT2. Vesicles isolated from endocrine cells expressing recombinant VGLUT3 accumulated l-glutamate with bioenergetic and pharmacological characteristics similar, but not identical, to those displayed by the type-1 and type-2 isoforms. Interestingly, the distribution of VGLUT3 mRNA was restricted to a small number of neurons scattered in the striatum, hippocampus, cerebral cortex, and raphe nuclei, in contrast to VGLUT1 and VGLUT2 transcripts, which are massively expressed in cortical and deep structures of the brain, respectively. At the ultrastructural level, VGLUT3 immunoreactivity was concentrated over synaptic vesicle clusters present in nerve endings forming asymmetrical as well as symmetrical synapses. Finally, VGLUT3-positive neurons of the striatum and raphe nuclei were shown to coexpress acetylcholine and serotonin transporters, respectively. Our study reveals a novel class of glutamatergic nerve terminals and suggests that cholinergic striatal interneurons and serotoninergic neurons from the brainstem may store and release glutamate.

15 November 2001 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
EHEtienne Herzog
Etienne Herzog
GBGian Carlo Bellenchi
Gian Carlo Bellenchi
CGChristelle Gras
Christelle Gras
VBVeronique Bernard
Veronique Bernard
PRPhilippe Ravassard
Philippe Ravassard
SMSalah El Mestikawy
Salah El Mestikawy
Before their exocytotic release during stimulation of nerve terminals, nonpeptide neurotransmitters are loaded into synaptic vesicles by specific transporters. Recently, a protein initially identified as brain-specific Na(+)-dependent inorganic phosphate transporter I (BNPI) has been shown to represent a vesicular glutamate transporter (VGLUT1). In this study, we investigated whether a highly homologous "differentiation-associated Na(+)-dependent inorganic phosphate transporter" (DNPI) is involved in glutamatergic transmission. Vesicles isolated from BON cells expressing recombinant DNPI accumulated l-glutamate with bioenergetical and pharmacological characteristics identical to those displayed by VGLUT1 and by brain synaptic vesicles. Moreover, DNPI localized to synaptic vesicles, at synapses exhibiting classical excitatory features. DNPI thus represents a novel vesicular glutamate transporter (VGLUT2). The distributions of each VGLUT transcript in brain were highly complementary, with only a partial regional and cellular overlap. At the protein level, we could only detect either VGLUT1- or VGLUT2-expressing presynaptic boutons. The existence of two VGLUTs thus defines distinct subsets of glutamatergic neurons.

1 August 2009 in Cell
Verified
Journal Article
Closed access
PCPatrick Collombat
Patrick Collombat
XXXiaobo Xu
Xiaobo Xu
PRPhilippe Ravassard
Philippe Ravassard
BSBeatriz Sosa-Pineda
Beatriz Sosa-Pineda
SDSébastien Dussaud
Sébastien Dussaud
AMAhmed Mansouri
Ahmed Mansouri

12 January 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LPLorenzo Pasquali
Lorenzo Pasquali
KGKyle J Gaulton
Kyle J Gaulton
SRSantiago A Rodríguez-Seguí
Santiago A Rodríguez-Seguí
LMLoris Mularoni
Loris Mularoni
IMIrene Miguel-Escalada
Irene Miguel-Escalada
JFJorge Ferrer
Jorge Ferrer
Jorge Ferrer and colleagues have mapped regulatory SNP variants associated in GWAS with type 2 diabetes risk and glycemic traits to large clusters of enhancer elements regulating the transcriptional identity of pancreatic β cells via a highly connected transcription factor network. Type 2 diabetes affects over 300 million people, causing severe complications and premature death, yet the underlying molecular mechanisms are largely unknown. Pancreatic islet dysfunction is central in type 2 diabetes pathogenesis, and understanding islet genome regulation could therefore provide valuable mechanistic insights. We have now mapped and examined the function of human islet cis-regulatory networks. We identify genomic sequences that are targeted by islet transcription factors to drive islet-specific gene activity and show that most such sequences reside in clusters of enhancers that form physical three-dimensional chromatin domains. We find that sequence variants associated with type 2 diabetes and fasting glycemia are enriched in these clustered islet enhancers and identify trait-associated variants that disrupt DNA binding and islet enhancer activity. Our studies illustrate how islet transcription factors interact functionally with the epigenome and provide systematic evidence that the dysregulation of islet enhancers is relevant to the mechanisms underlying type 2 diabetes.

1 October 2012 in Cell Metabolism
Verified
Journal Article
Closed access
IMIgnasi Morán
Ignasi Morán
IAİldem Akerman
İldem Akerman
MBMartijn van de Bunt
Martijn van de Bunt
RXRuiyu Xie
Ruiyu Xie
MBMarion Benazra
Marion Benazra
JFJorge Ferrer
Jorge Ferrer